Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®

Artiva Biotherapeutics is discontinuing development of its lead asset AlloNK (AB-101), including canceling the planned Phase 3 pivotal trial, after longer-term data failed to show durable clinical response and two Grade 5 patient deaths occurred in its Phase 2a study. The FDA asked Artiva to pause enrollment and dosing after a fatal leukoencephalopathy event assessed as likely fludarabine-associated neurotoxicity; a second sudden death was assessed as unrelated to study treatment.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.